Eli Lilly reported second-quarter revenue of $22.97 billion on Wednesday morning, up 48% from $15.56 billion a year ago and roughly $2.3 billion clear of the $20.7 billion Wall Street had penciled in. Non-GAAP earnings landed at $8.38 a share against a consensus near $6.01 — a 39% beat. Full-year revenue guidance went to $85–87 billion from $82–85 billion. The stock rose nearly 7% in early trading on a company already worth about $1.04 trillion.
That is the headline. Here is the line further down the product table: Mounjaro did $9.9 billion, up 91% — $4.8 billion from the United States and $5.2 billion from everywhere else. Revenue outside the U.S. grew 172%. Lilly’s biggest product now sells more abroad than at home.
That crossover did not happen because American demand cooled. U.S. Mounjaro sales are still growing, and Zepbound added $4.9 billion domestically on 44% growth. It happened because volume abroad detonated — much of it from China adding Mounjaro to its National Reimbursement Drug List in Q1. Lilly said the international gain came primarily from volume, “partially offset by lower realized prices.” That clause is the whole story.
Our take: Lilly is no longer an American drug company with export sales. On its single largest product it is a global volume business headquartered in Indianapolis — and it got there by accepting a lower price to get onto a foreign formulary. Everyone models the U.S. obesity market. Almost nobody models the second one. From here the number to track isn’t revenue, it’s whether that 172% international line survives lapping its own reimbursement surge.
The raise is mostly the beat
Run the arithmetic. The old midpoint was $83.5 billion; the new one is $86 billion — $2.5 billion of additional 2026 revenue. Q2 alone came in roughly $2.3 billion above where the street had it. So Lilly raised the back half of the year by something like $200 million, against a business clearing $23 billion a quarter.
The band also tightened, from $3 billion wide to $2 billion. A company that beats by 39% and raises by roughly the size of the beat is either treating the beat as timing or choosing credibility over a bigger headline. Both beat the alternative, which is a raise that quietly borrows from Q4.
What a lower price buys
The uncomfortable half of this quarter is that Lilly’s fastest growth is now its cheapest growth. Net prices fell in the U.S. on Zepbound and fell abroad on Mounjaro, and revenue grew anyway because units grew faster than price fell. That works beautifully while capacity is the binding constraint and every dose made is a dose sold. It works far less well the day supply catches demand and price is the only lever left.
For now it is also plainly the right trade. Getting the drug onto China’s reimbursement list at a discount buys a market a premium price would have left empty for years. Volume at a discount compounds; price with no volume does not. Same logic as why the 100% drug tariff mattered less than its headline — the industry’s real fight is access, not list price.
Note what did not drive the quarter. Reported EPS was $7.94 against $8.38 non-GAAP, the gap in acquisition-related charges — Lilly has spent 2026 buying, including the $2.8 billion atai Beckley deal. None of the growth above came from anything it bought. It came from two drugs it already owned.
What to watch
- The Q3 international line. 172% was measured against a quarter with no NRDL listing in it. The next comparison includes one.
- Whether the second half moves. Management added roughly $200 million to H2. If Q3 prints like Q2, the range moves again — and holding it back becomes the story.
- Capacity. Volume-led growth at falling prices only works if the plants keep up.
- Zepbound’s U.S. net price. 44% growth on a declining price means scripts are doing all the work. Fine engine, until scripts flatten.
Compare AMD, which beat every line on Tuesday and fell 8%. The market did not punish AMD for missing; it punished a number nobody modeled. Lilly beat everything the street models and rose — while the number nobody models flipped in its favor.